Scribe Therapeutics: Funding, Investors & Team (Sep 2026)
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.
Scribe Therapeutics has raised $25.0M across 2 funding rounds on record, the most recent an undisclosed round of $25.0M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Scribe Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Scribe Therapeutics Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Scribe Therapeutics announced an undisclosed round in May 2023; the amount was not disclosed.
3.1 years later, an undisclosed round of $25.0M was announced in Jun 2026.
Scribe Therapeutics Founders and Leadership Team
Contact details for the Scribe Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Scribe Therapeutics Funding Compared to Other Biotechnology Startups
Scribe Therapeutics' latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Scribe Therapeutics in Biotechnology and Alameda
Companies Similar to Scribe Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Scribe Therapeutics Funding FAQs
What does Scribe Therapeutics do?
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.
How much funding has Scribe Therapeutics raised?
Scribe Therapeutics has raised $25.0M across 2 rounds on record. The most recent is an undisclosed round of $25.0M announced in Jun 2026.
When did Scribe Therapeutics last raise funding?
Scribe Therapeutics' most recent funding round on record is an undisclosed round of $25.0M, announced in Jun 2026.
Who is the CEO of Scribe Therapeutics?
Benjamin Oakes is listed as CEO at Scribe Therapeutics.
Where is Scribe Therapeutics headquartered?
Scribe Therapeutics is based in Alameda, California, United States.
How many employees does Scribe Therapeutics have?
Scribe Therapeutics is in the 51-100 employee band.
How does Scribe Therapeutics' funding compare to other Biotechnology startups?
Scribe Therapeutics' latest round of $25.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Scribe Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Scribe Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.